Taraxacum Officinale Flowering Top

Dosage for Taraxacum Officinale Flowering Top is highly individualized and must be determined by an allergy specialist based on the patient's sensitivity levels. There is no 'standard' dose that applies to all patients.

Diagnostic Testing Dosage

• Prick-Puncture Method: Usually, one drop of a 1:10 or 1:20 w/v glycerinated extract is applied to the skin. A sterile lancet is used to prick the skin through the drop. A positive control (histamine) and a negative control (saline/glycerin) are used simultaneously for comparison.
• Intradermal Testing: If the prick test is negative but clinical suspicion remains high, a 1:100 or 1:1000 w/v aqueous extract may be injected (0.02 to 0.05 mL) to create a small bleb on the skin.

Immunotherapy Dosage

• Build-up Phase: Treatment typically begins with a very dilute solution (e.g., 1:100,000 w/v). Injections are given once or twice weekly, with the dose increasing by 20% to 50% each time, provided no significant local or systemic reactions occur.
• Maintenance Phase: Once the 'maintenance dose' is reached (the highest dose tolerated by the patient that provides symptomatic relief), the frequency of injections is reduced to once every 2 to 4 weeks.

Taraxacum Officinale Flowering Top may be used in children, but extreme caution is required. The dosage principles are generally the same as for adults, but the starting dose in immunotherapy may be even more conservative. According to the American Academy of Pediatrics, immunotherapy is generally not initiated in children under the age of 5 due to the difficulty of the child communicating early symptoms of a systemic reaction.

Renal Impairment

No specific dosage adjustments are typically required for patients with renal impairment, as the systemic protein load is minimal. However, the patient's overall health must be stable before administration.

Hepatic Impairment

No specific adjustments are documented for hepatic impairment. The metabolism of these proteins occurs via general proteolytic pathways rather than specific hepatic CYP450 enzymes.

Elderly Patients

Older adults may have a reduced 'wheal and flare' response due to skin changes. Clinicians may need to adjust their interpretation of diagnostic tests. Furthermore, the risk of cardiac complications during a systemic reaction is higher in this population.

This medication is never self-administered by the patient at home. It is administered via:

• Epicutaneous (Prick) Testing: Applied to the forearm or back.
• Subcutaneous Injection: Administered into the loose subcutaneous tissue of the upper arm, alternating arms with each dose.

Patients should remain in the doctor's office for at least 30 minutes following any administration to monitor for signs of a systemic allergic reaction.

In the context of immunotherapy, a missed dose can disrupt the desensitization process. If a dose is missed for more than one week beyond the scheduled interval, the healthcare provider may need to reduce the next dose to ensure safety. If several weeks are missed, the build-up process may need to be restarted from a lower concentration.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, leading to a systemic reaction. Symptoms of an overdose (anaphylaxis) include:

• Generalized hives (urticaria)
• Swelling of the throat or tongue
• Difficulty breathing or wheezing
• Rapid drop in blood pressure (hypotension)
• Dizziness or loss of consciousness

Emergency treatment requires the immediate administration of epinephrine (adrenaline) and supportive care.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to use these products without medical guidance.

The most common side effects of Taraxacum Officinale Flowering Top are localized to the site of administration. These are often expected as part of the diagnostic process.

• Local Wheal and Flare: A raised, itchy bump (wheal) surrounded by redness (flare). In diagnostic testing, this is the intended result for sensitized individuals. It typically appears within 15 minutes and resolves within 1 to 2 hours.
• Local Swelling and Redness: In immunotherapy, swelling at the injection site (up to the size of a half-dollar) is common. It may feel warm, itchy, or slightly tender.
• Itching (Pruritus): Intense itching at the site of the skin test or injection.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter at the injection site. This may persist for 24 to 48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Mild Nasal Congestion: A slight increase in hay fever-like symptoms shortly after administration.

• Systemic Urticaria: Hives appearing on parts of the body far from the injection site.
• Vasovagal Reaction: Fainting or lightheadedness caused by the stress of the needle or procedure, rather than an allergic reaction itself.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).

> Warning: Stop the procedure and call for emergency assistance if any of the following occur. These are signs of anaphylaxis, a life-threatening emergency.

• Respiratory Distress: Sudden wheezing, chest tightness, or shortness of breath. This indicates a narrowing of the airways.
• Angioedema: Significant swelling of the lips, tongue, or throat that may obstruct breathing.
• Hypotension: A sudden drop in blood pressure, often characterized by extreme dizziness, pallor, or fainting.
• Cyanosis: A bluish tint to the skin or lips, indicating a lack of oxygen.
• Generalized Anaphylaxis: A combination of the above symptoms, often accompanied by a sense of 'impending doom.'

There are no known long-term 'toxic' side effects of Taraxacum Officinale Flowering Top when used correctly. The primary long-term risk is the potential for the patient to become more sensitized if the immunotherapy is not managed correctly, though the goal is the opposite. Some patients may develop persistent nodules (small lumps) at the site of repeated injections, which are usually benign.

Allergenic extracts, including Taraxacum Officinale Flowering Top, carry a standard FDA-mandated warning regarding the risk of severe systemic reactions.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylaxis. It must only be administered in a clinical setting by healthcare providers equipped with the tools (epinephrine, oxygen, IV fluids) and training to manage such emergencies. Patients with unstable asthma are at a significantly higher risk for fatal reactions and must be evaluated carefully before use.

Report any unusual symptoms to your healthcare provider immediately. Adverse events can also be reported to the FDA's MedWatch program.

Taraxacum Officinale Flowering Top is a potent biological agent. Its use is restricted to diagnostic and therapeutic applications under the supervision of specialists. Patients must be aware that while the extract is derived from a common plant, in its concentrated clinical form, it can trigger profound immunological responses. It is essential to provide a complete medical history, especially regarding previous allergic reactions and current respiratory health.

No FDA black box warnings for Taraxacum Officinale Flowering Top specifically, but it falls under the general black box warning for all Allergenic Extracts. The warning emphasizes that these products may cause severe, life-threatening anaphylaxis. Injections must be supervised for at least 30 minutes, and the product should not be used in patients with severe, unstable, or steroid-dependent asthma unless the benefits clearly outweigh the risks.

Allergic Reactions / Anaphylaxis Risk

The primary risk is a systemic allergic reaction. This risk is increased if the patient is currently experiencing a flare-up of their allergy symptoms or if they have recently exercised, as increased circulation can speed up the systemic absorption of the allergen.

Asthma Status

Patients with poorly controlled asthma are at the highest risk for a fatal reaction to allergenic extracts. According to the 2024 AAAAI guidelines, a patient's Peak Expiratory Flow (PEF) or FEV1 should be assessed if they are symptomatic before an injection is administered.

Beta-Blocker Use

Patients taking beta-blockers (medications for blood pressure or heart conditions) may be resistant to the effects of epinephrine. If a patient on beta-blockers has an anaphylactic reaction to Taraxacum Officinale Flowering Top, the standard emergency treatment may not work effectively, making the reaction much more dangerous.

• Observation Period: A mandatory 30-minute wait in the clinic after every administration.
• Skin Test Interpretation: Measurement of the wheal (the raised area) and flare (the red area) in millimeters.
• Lung Function: Periodic monitoring of lung function in asthmatic patients receiving immunotherapy.

Generally, Taraxacum Officinale Flowering Top does not interfere with the ability to drive or operate machinery. However, if a patient experiences a vasovagal reaction (fainting) or a systemic reaction involving dizziness, they should not drive until they are fully recovered and cleared by a medical professional.

Alcohol consumption should be avoided on the day of an allergy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially mask or exacerbate the symptoms of an allergic reaction.

There is no 'withdrawal' syndrome associated with Taraxacum Officinale Flowering Top. However, stopping immunotherapy prematurely will likely result in the return of allergy symptoms upon exposure to dandelions. If a patient experiences a severe systemic reaction, the healthcare provider may decide to discontinue the treatment permanently.

> Important: Discuss all your medical conditions with your healthcare provider before starting Taraxacum Officinale Flowering Top.

There are few absolute drug-drug contraindications, but certain combinations significantly increase the risk of a catastrophic outcome:

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs block the receptors that epinephrine needs to work. If a patient has a severe reaction to the extract, epinephrine may fail to reverse the airway constriction and low blood pressure, leading to potential fatality.

• Selective Beta-1 Blockers (e.g., Metoprolol, Atenolol): While slightly safer than non-selective versions, they still pose a risk of interfering with anaphylaxis treatment. Use with extreme caution.
• ACE Inhibitors (e.g., Lisinopril): Some studies suggest ACE inhibitors may increase the risk of more severe systemic reactions or interfere with the body's natural compensatory mechanisms during anaphylaxis.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine if it is administered for a reaction, leading to a dangerous spike in blood pressure (hypertensive crisis).

• Antihistamines (e.g., Loratadine, Cetirizine, Diphenhydramine): These medications will suppress the skin's reaction to the Taraxacum Officinale Flowering Top extract. This leads to 'false negative' results. Patients are usually instructed to stop antihistamines 3 to 7 days before diagnostic testing.
• H2 Blockers (e.g., Famotidine): Like H1 antihistamines, these can also dampen the allergic response during testing.
• Topical Corticosteroids: If applied to the site of the skin test, they can suppress the inflammatory response and invalidate the test results.

There are no direct food interactions with the extract itself. However, patients with a dandelion allergy may experience 'Oral Allergy Syndrome' (OAS) when eating certain foods. This is due to cross-reactivity between dandelion proteins and proteins in:

• Honey: May contain dandelion pollen.
• Chamomile tea.
• Sunflower seeds.
• Artichokes.

• Echinacea and Feverfew: These plants are in the same family (Asteraceae) as dandelions. Taking these supplements may increase the patient's overall 'allergic load' and sensitivity during testing or treatment.
• St. John's Wort: May increase skin sensitivity to light, but its interaction with allergenic extracts is not clinically well-defined.

Taraxacum Officinale Flowering Top does not typically interfere with standard blood chemistry or hematology tests. However, it will directly affect:

• Skin Prick Tests: As intended.
• Serum Specific IgE (ImmunoCAP): Immunotherapy will eventually lead to changes in measured IgE levels for dandelion, which is a sign of the treatment's effect rather than an 'interference.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Taraxacum Officinale Flowering Top must NEVER be used in the following circumstances:

1. 1Severe, Uncontrolled Asthma: Patients whose asthma is not stable are at an unacceptably high risk of fatal bronchospasm during a systemic reaction. The risk of death outweighs the diagnostic or therapeutic benefit.
2. 2Previous Life-Threatening Reaction: If a patient has previously had a near-fatal reaction to dandelion extract or a closely related allergenic extract, further use is contraindicated.
3. 3Acute Infection: Administration should be delayed if the patient has a fever or a significant respiratory infection, as this can lower the threshold for a systemic reaction.
4. 4Recent Myocardial Infarction: Patients who have had a heart attack within the last 3-6 months should not undergo testing or immunotherapy due to the cardiac stress of a potential allergic reaction.

These conditions require a careful risk-benefit analysis by the physician:

• Pregnancy: Immunotherapy is generally not initiated during pregnancy because of the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby). However, if a patient is already on a stable maintenance dose, it may be continued.
• Autoimmune Diseases: There is theoretical concern that stimulating the immune system with extracts could exacerbate conditions like Lupus or Rheumatoid Arthritis.
• Malignancy: Patients with active cancer may have altered immune responses.
• Beta-Blocker Therapy: As discussed, this makes managing a reaction much more difficult.

Patients who are allergic to Taraxacum Officinale Flowering Top are very likely to be cross-sensitive to other members of the Asteraceae (Compositae) family. This includes:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Sunflowers

A positive reaction to dandelion should alert the clinician to potential sensitivities across this entire botanical family.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Taraxacum Officinale Flowering Top.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Taraxacum Officinale Flowering Top in pregnant women. Animal reproduction studies have not been conducted. The primary concern during pregnancy is not the extract itself, but the risk of a systemic reaction (anaphylaxis). Anaphylaxis in the mother can cause a sudden drop in blood pressure, leading to decreased uterine blood flow and fetal distress or death. Most allergists recommend against starting new immunotherapy during pregnancy but may continue maintenance doses if the patient is stable.

It is not known whether the allergenic proteins in Taraxacum Officinale Flowering Top are excreted in human milk. Because these are large proteins that are likely digested in the infant's gut, the risk to a nursing child is considered low. However, the mother should be monitored for systemic reactions, which could theoretically interfere with lactation or the ability to care for the infant.

Taraxacum Officinale Flowering Top is used in children for both diagnosis and treatment. However, the safety and efficacy of immunotherapy in children under age 5 have not been established. Younger children may be unable to articulate the early symptoms of a systemic reaction (such as an itchy throat or a 'funny' feeling), which can delay the administration of life-saving epinephrine.

Clinical studies of allergenic extracts often do not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. In geriatric patients, the physician must consider the higher prevalence of underlying cardiovascular disease. An allergic reaction in an older adult is more likely to trigger a cardiac event (such as an arrhythmia or heart attack).

Specific studies in patients with renal impairment have not been conducted. However, since the protein load in a diagnostic test or immunotherapy injection is extremely small (micrograms), it is unlikely to pose a risk to patients with kidney disease. The clinician should ensure the patient is hemodynamically stable.

There are no specific precautions for patients with liver disease. The metabolic clearance of allergenic proteins does not rely on the liver's detoxification pathways.

> Important: Special populations require individualized medical assessment by an allergy and immunology specialist.

Taraxacum Officinale Flowering Top acts as an exogenous antigen. Its primary molecular targets are the High-Affinity IgE Receptors (FcεRI) located on the surface of mast cells and basophils.

1. 1Sensitization Phase: In allergic individuals, B-cells have already produced IgE antibodies specific to dandelion proteins. These IgE molecules are 'loaded' onto the FcεRI receptors.
2. 2Effector Phase (Testing): When the extract is introduced, the multivalent dandelion antigens bind to and cross-link adjacent IgE molecules. This physical bridging triggers a signal transduction cascade involving tyrosine kinases (like Syk), leading to the influx of calcium and the release of pre-formed mediators (histamine) and newly synthesized mediators (leukotrienes).
3. 3Modulation Phase (Immunotherapy): Repeated exposure leads to the induction of T-regulatory cells that secrete IL-10 and TGF-beta, which promote a class switch in B-cells from IgE to IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody, intercepting the allergen before it can reach the mast-cell-bound IgE.

• Onset of Action (Diagnostic): 15 to 20 minutes for a wheal and flare reaction.
• Duration of Action (Diagnostic): The visible skin reaction typically fades within 2 hours, though late-phase reactions can occur 4-8 hours later.
• Therapeutic Effect: In immunotherapy, clinical improvement typically begins 3-6 months after reaching the maintenance dose, with maximum benefit often seen after 12-24 months of continuous treatment.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | High (to specific IgE and IgG) |

| Half-life | Minutes (proteins); Years (immunological memory) |

| Tmax | 15-20 minutes (local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (metabolites) |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides. Key allergens in Taraxacum often include proteins in the 10-70 kDa range.
• Solubility: Highly soluble in aqueous solutions and glycerin-saline mixtures.
• Source: Collected from the flowering tops (capitula) of Taraxacum officinale during peak anthesis (flowering period).

Taraxacum Officinale Flowering Top is classified as a Non-Standardized Plant Allergenic Extract. It is grouped with other weed and flower extracts used in the 'Compositae' or 'Asteraceae' diagnostic panels. Unlike 'Standardized' extracts (like Ragweed or Grass), its potency is not measured by a specific bioassay but by its concentration relative to the raw starting material.